The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

In AERIFY-2, however, itepekimab failed to hit this same threshold, showing only a 2% reduction in exacerbations at 52 weeks. “Sentiment has undoubtedly been poor for REGN shares of late following the ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says.

Otsuka has shared data behind its kidney disease drug’s win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio levels.

As psychedelics gain traction as potential treatments for mental health disorders, an international study stands to improve the rigor and reliability of clinical research.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former smokers who have inadequately controlled chronic obstructive ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant ...

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug candidate’s late-stage trials.